Home > Publications Database > Multicenter Collaborative Study to Optimize Mass Spectrometry Workflows of Clinical Specimens. > print

001     266784
005     20240808164705.0
024 7 _ |a pmc:PMC10775142
|2 pmc
024 7 _ |a 10.1021/acs.jproteome.3c00473
|2 doi
024 7 _ |a pmid:38015820
|2 pmid
024 7 _ |a 1535-3893
|2 ISSN
024 7 _ |a 1535-3907
|2 ISSN
024 7 _ |a altmetric:156904781
|2 altmetric
037 _ _ |a DZNE-2024-00042
041 _ _ |a English
082 _ _ |a 540
100 1 _ |a Kardell, Oliver
|0 0000-0002-6703-7997
|b 0
245 _ _ |a Multicenter Collaborative Study to Optimize Mass Spectrometry Workflows of Clinical Specimens.
260 _ _ |a Washington, DC
|c 2024
|b ACS Publications
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1705491843_18423
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The foundation for integrating mass spectrometry (MS)-based proteomics into systems medicine is the development of standardized start-to-finish and fit-for-purpose workflows for clinical specimens. An essential step in this pursuit is to highlight the common ground in a diverse landscape of different sample preparation techniques and liquid chromatography-mass spectrometry (LC-MS) setups. With the aim to benchmark and improve the current best practices among the proteomics MS laboratories of the CLINSPECT-M consortium, we performed two consecutive round-robin studies with full freedom to operate in terms of sample preparation and MS measurements. The six study partners were provided with two clinically relevant sample matrices: plasma and cerebrospinal fluid (CSF). In the first round, each laboratory applied their current best practice protocol for the respective matrix. Based on the achieved results and following a transparent exchange of all lab-specific protocols within the consortium, each laboratory could advance their methods before measuring the same samples in the second acquisition round. Both time points are compared with respect to identifications (IDs), data completeness, and precision, as well as reproducibility. As a result, the individual performances of participating study centers were improved in the second measurement, emphasizing the effect and importance of the expert-driven exchange of best practices for direct practical improvements.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 2 |a Tandem Mass Spectrometry: methods
|2 MeSH
650 _ 2 |a Chromatography, Liquid: methods
|2 MeSH
650 _ 2 |a Workflow
|2 MeSH
650 _ 2 |a Reproducibility of Results
|2 MeSH
650 _ 2 |a Plasma: chemistry
|2 MeSH
650 _ 7 |a LC–MS
|2 Other
650 _ 7 |a LC–MS
|2 Other
650 _ 7 |a LC–MS
|2 Other
650 _ 7 |a CSF
|2 Other
650 _ 7 |a LC–MS
|2 Other
650 _ 7 |a R package mpwR
|2 Other
650 _ 7 |a clinical specimen
|2 Other
650 _ 7 |a data-dependent acquisition
|2 Other
650 _ 7 |a data-independent acquisition
|2 Other
650 _ 7 |a interlaboratory
|2 Other
650 _ 7 |a intralaboratory
|2 Other
650 _ 7 |a mass spectrometry
|2 Other
650 _ 7 |a plasma
|2 Other
650 _ 7 |a round-robin study
|2 Other
700 1 _ |a von Toerne, Christine
|b 1
700 1 _ |a Merl-Pham, Juliane
|b 2
700 1 _ |a König, Ann-Christine
|b 3
700 1 _ |a Blindert, Marcel
|b 4
700 1 _ |a Barth, Teresa K
|b 5
700 1 _ |a Mergner, Julia
|b 6
700 1 _ |a Ludwig, Christina
|0 0000-0002-6131-7322
|b 7
700 1 _ |a Tüshaus, Johanna
|0 P:(DE-2719)2812852
|b 8
|u dzne
700 1 _ |a Eckert, Stephan
|b 9
700 1 _ |a Müller, Stephan A
|0 P:(DE-2719)2810938
|b 10
|u dzne
700 1 _ |a Breimann, Stephan
|0 P:(DE-2719)9001161
|b 11
|u dzne
700 1 _ |a Giesbertz, Pieter
|0 P:(DE-2719)9001718
|b 12
|u dzne
700 1 _ |a Bernhardt, Alexander Maximilian
|0 P:(DE-2719)9002620
|b 13
|u dzne
700 1 _ |a Schweizer, Lisa
|b 14
700 1 _ |a Albrecht, Vincent
|b 15
700 1 _ |a Teupser, Daniel
|b 16
700 1 _ |a Imhof, Axel
|0 0000-0003-2993-8249
|b 17
700 1 _ |a Kuster, Bernhard
|0 0000-0002-9094-1677
|b 18
700 1 _ |a Lichtenthaler, Stefan F
|0 P:(DE-2719)2181459
|b 19
|u dzne
700 1 _ |a Mann, Matthias
|b 20
700 1 _ |a Cox, Jürgen
|0 0000-0001-8597-205X
|b 21
700 1 _ |a Hauck, Stefanie M
|0 0000-0002-1630-6827
|b 22
773 _ _ |a 10.1021/acs.jproteome.3c00473
|g Vol. 23, no. 1, p. 117 - 129
|0 PERI:(DE-600)2065254-9
|n 1
|p 117 - 129
|t Journal of proteome research
|v 23
|y 2024
|x 1535-3893
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/266784/files/DZNE-2024-00042.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/266784/files/DZNE-2024-00042.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:266784
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 8
|6 P:(DE-2719)2812852
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2810938
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)9001161
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)9001718
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)9002620
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 19
|6 P:(DE-2719)2181459
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-23
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J PROTEOME RES : 2022
|d 2023-08-23
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-23
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-23
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-23
920 1 _ |0 I:(DE-2719)1110006
|k AG Lichtenthaler
|l Neuroproteomics
|x 0
920 1 _ |0 I:(DE-2719)1110007
|k AG Haass
|l Molecular Neurodegeneration
|x 1
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1110006
980 _ _ |a I:(DE-2719)1110007
980 _ _ |a I:(DE-2719)1111015
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21